Proteomics International Laboratories Ltd (PIQ.AX) March 2023 Quarterly Activities Report
Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 31 March 2023 and subsequent to the period end.
- Novel blood test for endometriosis presented at international conference: Potential worldfirst blood test to improve screening for a disease that affects 1 in 9 women
- Major milestones achieved as CPT PLA reimbursement code approved and becomes effective for PromarkerD in the United States: Code is key to PromarkerD being covered by both Medicare and private health insurers in the US
- US licensing negotiation in closing stages: Proteomics International finalising terms with Sonic Healthcare USA to bring PromarkerD to the United States
- Clinical Advisory Board expanded to support PromarkerD USA and global rollout: New members comprise highly respected healthcare professionals and key opinion leaders (KOLs) specialising in primary care diabetes education and management
- Distribution agreement for PromarkerD in Britain extended: Deal with medical diagnostics company Apacor Limited extended for a further five years
- Application for PromarkerD listing on Australian Medicare Benefits Schedule (MBS) to be resubmitted: review committee notes potential wide uptake of the test and long term savings to the health system
- Exercise of options: The Company's balance sheet was boosted significantly following the exercise of options raising $3.1 million before costs.
Proteomics International's activities fall into three key areas:
(i) commercialisation of PromarkerD, the predictive test for diabetic kidney disease (DKD)
(ii) R&D for new diagnostic tests using the PromarkerTM pipeline
(iii) analytical services on a commercial basis
*To view the full Quarterly Report, please visit:
https://abnnewswire.net/lnk/JSQ3QF0B
Dr Richard Lipscombe Managing Director Proteomics International Laboratories Ltd T: +61 8 9389 1992 E: enquiries@proteomicsinternational.com Dirk van Dissel Investor Relations & Corporate Advisor Candour Advisory T: +61 408 326 367 E: dirk@candouradvisory.com.au Kyle Moss Corporate Advisor Euroz Hartleys T: +61 8 9488 1400 E: kmoss@eurozhartleys.com
News Provided by ABN Newswire
